Drug Dissolution: Requirements and Profile Comparison

The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:

1. First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.
2. Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final stage.
3. Final Stage: The average of twenty-four units must meet the criteria from the second stage, ensuring that none fall below Q - 25% to pass.

In parallel, dissolution profile comparisons play a pivotal role in the practical development of bioequivalent drug products and in demonstrating equivalence following formulation changes. This process involves calculating the difference factor, f₁, and the similarity factor, f₂. Two dissolution profiles are identical if f₁ is 0 and f₂ is 100.

Evaluating the similarity between dissolution profiles entails specific conditions:

• A minimum of three dissolution time points must be measured.
• Twelve drug products are tested for dissolution in the test and reference cases.
• At most, one mean value exceeding 85% dissolved is allowable for each product.
• The standard deviation of the mean of any product should not exceed 10% from the second to the last dissolution time point.

These rigorous criteria and comparisons ensure the reliability and consistency of dissolution profile data, thereby contributing to the development and assessment of pharmaceutical products.